Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
08 September 2021 - 9:32PM
Diffusion Pharmaceuticals Inc. (NASDAQ:
DFFN) (“Diffusion” or the “Company”), an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief
Executive Officer, will present at the H.C. Wainwright 23rd
Annual Global Investment Conference taking place September 13-15,
2021. The prerecorded presentation will be available starting at 7
a.m. ET on September 13, 2021 and will be accessible via the
conference’s virtual platform by registered conference attendees.
The presentation will be archived and available for viewing for 90
days, following the conference.
Dr. Cobuzzi will provide an overview of
Diffusion’s business highlights and recent corporate and clinical
achievements, as well as anticipated milestones in the clinical
programs for trans sodium crocetinate (TSC), Diffusion’s lead
product candidate. Diffusion has completed the first of three
Oxygenation Trials, which are intended to guide the selection of
indications and doses to be pursued for future development of TSC.
Diffusion plans to select the initial indication by year-end 2021,
and initiate a Phase 2 trial in that indication in the first half
of 2022.
Additionally, Dr. Cobuzzi and members of the
Diffusion management team will be participating in virtual
one-on-one meetings with registered investors and pharmaceutical
company executives.
Details of the presentation are as
follows:
Event: |
H.C. Wainwright 23rd Annual Global Investment Conference |
Date: |
September 13-15, 2021 |
Time: |
Presentation available starting at 7 a.m. ET on September 13,
2021 |
Registration: |
https://hcwevents.com/annualconference/ |
Following the conclusion of the event, a
recording of Dr. Cobuzzi’s presentation will be available under
“Presentations” in the Investors section of the Company’s website
at https://www.diffusionpharma.com/.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most. Diffusion’s lead product candidate, TSC, is being developed
to enhance the diffusion of oxygen to tissues with low oxygen
levels, also known as hypoxia, a serious complication of many of
medicine’s most intractable and difficult-to-treat conditions. In
addition to TSC, Diffusion’s product candidate DFN-529, a novel,
allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage
development. For more information, please visit us at
www.diffusionpharma.com.
Forward-Looking Statements
This press release includes express and implied
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
regarding the Company’s near-term strategic priorities and the
potential therapeutic value of TSC. The Company may, in some cases,
use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately,” or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Although the Company believes that it has a reasonable
basis for each forward-looking statement contained herein,
forward-looking statements by their nature involve risks and
uncertainties, known and unknown, many of which are beyond the
Company’s control, and as a result, the Company’s actual results
could differ materially from those expressed or implied in any
forward-looking statement. Particular risk and uncertainties
include, among other things, those related to: the Company’s
ability to design, initiate, enroll, execute, and complete its
ongoing and planned studies evaluating TSC; the optimal doses and
dosing regimens of TSC in connection with the potential treatment
of any particular disease or indication; general economic,
political, business, industry, and market conditions, including the
ongoing COVID-19 pandemic; and the other factors discussed under
the heading “Risk Factors” in the Company’s filings most recent
Annual Report on Form 10-K and other filings with the U.S.
Securities and Exchange Commission. Any forward-looking statements
in this press release speak only as of the date hereof (or such
earlier date as may be identified) and, except as required by
applicable law, rule, or regulation, the Company undertakes no
obligation to update any such statements after the date hereof.
ContactsInvestors:Tiberend
Strategic Advisors, Inc. Maureen McEnroe, CFA / Lisa
Sher mmcenroe@tiberend.com / lsher@tiberend.com
Media:Kate BarretteRooneyPartners(212)
223-0561Kbarrette@rooneypartners.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2024 to May 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From May 2023 to May 2024